The aim of this prospective study was to assess the feasibility of a state-of-the-art clinical PET/CT scanner for in vivo tumor imaging in mice in comparison to a small animal PET scanner and a small animal CT scanner.
Introduction
Small animal models of rats and mice are widely used in biomedical research for mimicking and studying humans in healthy or diseased situations, because Technology in Cancer Research & Treatment, Volume 5, Number 5, October 2006 of their genetic resemblance to humans and the feasibility of gene transfer and gene modification (1, 2) . Planar scintigraphy, single photon emission computed tomography (SPECT), and positron emission tomography (PET) are in vivo imaging techniques that can assess molecular aspects and metabolic alterations using small amounts of radioactive labeled molecules, which are fundamental for cancer detection and evaluation of therapeutical response and recurrence. The large variety of PET imaging devices developed for small animals thus far indicates that there is a strong interest in applying non-invasive imaging techniques to animal research (2). The main drawback of PET imaging is the lack of an anatomical reference frame. Combined PET and CT imaging devices offer several advantages over individual PET and CT imaging and improve the diagnostic value of both imaging modalities in the identification and characterization of malignancies. Therefore, PET/CT is a highly valuable oncological imaging modality.
In medical research, 18 F-labeled 1-α-D-(5-fluoro-5-deoxyarabinofuranosyl)-2-nitroimidazole ( 18 F-fluoroazomycin arabinoside; 18 F-FAZA) is a promising radioactive tracer for patients with cancer because it can be used non-invasively in the detection of tumor hypoxia in humans, as well as in small animals (3). As tumor hypoxia has a major negative predictive value for local tumor progression, likeliness of metastasis, and overall tumor prognosis in several types of human cancer, the presence of tumor tissue hypoxia is relevant in Figure 1 : Female NMRI nude mouse with a murine mammary carcinoma (EMT6) at the right hind limb (arrow) with a tumor volume of 557 μl as measured by CT of the clinical PET/CT. 18 F-FAZA was used for imaging of tumor hypoxia. Corresponding coronal views through the mice body at the level of maximal hypoxia tracer accumulation using the clinical PET/ CT (a-c) showing the CT-based attenuation corrected 18 F-FAZA PET image (a), the high-resolution CT image (b) and the automatic fused PET and CT image (PET/CT) (c) and using the dedicated small animal PET and CT (d-f) showing the 18 F-FAZA PET image (d), the high-resolution CT image (e), and the manually fused PET and CT image (PET/CT) (f). The mean tumor-to-background ratio for the PET scanner of the clinical PET/ CT was 1.4 and for the dedicated small animal PET scanner 2.7. Due to the low spatial resolution and partial volume effects, the radiotracer uptake in the PET images of the clinical PET/CT presented blurred. A radioactivity accumulation can also be seen in the small and large intestine due to the physiological tracer elimination. predicting prognosis and response to current radiation treatment (4). In addition, tumor cell hypoxia has a negative effect on anticancer treatment, given that hypoxic cells are 2-3 times more resistant to a single fraction of ionizing radiation than those with normal oxygenation levels (5).
The objective of this study was to evaluate the feasibility for in vivo imaging of tumor-bearing mice using a state-ofthe-art clinical PET/CT scanner with high-resolution scanning and reconstruction protocols. The results were compared with those from dedicated devices for small animal PET and small animal CT.
Materials and Methods

Animals
We consecutively examined 17 female Naval Medical Research Institute (NMRI) nude mice with a state-of-the-art clinical PET/CT, a small animal PET, and a small animal CT. The radioactive tracer, 18 F-FAZA, was used as PET tracer for detection and imaging of regional tumor hypoxia. For the tumor hypoxia model, the murine mammary carcinoma (EMT6) was transplanted subcutaneously on the right hind limb of 8-week-old female NMRI nude mice (20-25 g). 11 MBq (0.3 mCi) was injected through a lateral tail vein three hours before the start of imaging. During imaging, mice were anesthetized by intraperitoneal injection of ketamine (70 mg/kg) and xylazine (7 mg/kg), catheterized and positioned prone inside the clinical PET/CT, the small animal PET, and the small animal CT. The examinations of the same mouse were performed within half an hour, beginning with eight nude mice in the clinical PET/CT and in nine nude mice in the small animal PET and small animal CT. All animal experiments were conducted in compliance with the guidelines for the use of living animals in scientific studies and the German law for protection of animals.
Clinical PET/CT Scanner
High-resolution CT examinations were performed using a multi-detector (16-slice) computed tomography (MDCT) scanner incorporated in the clinical PET/CT (biograph Sensation 16 ® ; Siemens AG, Erlangen, Germany). An anterior-posterior scout-view was obtained for planning and determining the location of the scanning volume. Scans were acquired in a cranio-caudal direction using a tube voltage of 120 KV, tube current of 120 mAs, slice collimation of 16 × 0.75 mm, table feed of 12.0 mm, rotation time of 1.0 second and a 512 × 512 matrix. After data acquisition, the axial images were reconstructed in order to reduce the primary field of view (FOV) to 50 mm to decrease pixel size and provide high spatial resolution using a 0.4 mm increment, a 180º interpolation and high-resolution software algorithm (Kernel B60s sharp).
High-resolution PET examinations were performed using a full-ring Pico-3D PET scanner incorporated in the clinical PET/CT with a high-count-rate lutetium oxyorthosilicate (LSO) detector. The anterior-posterior scout view from CT was used for planning and determining the location of the bed position. After 12 minutes of data acquisition, PET images were reconstructed in order to reduce the primary field of view with a sinogram trim factor of three to decrease pixel size and provide high spatial resolution using a 512 × 512 matrix, an iterative reconstruction method (attenuation weighted -ordered subset expectation maximization (AW-OSEM), 4 iterations, each 8 subsets) and a gaussian filter.
The image fusion of the PET and CT data sets was performed by an automatic image fusion system (MSViewer; Siemens AG, Erlangen, Germany).
Dedicated Small Animal PET and CT Scanner
The CT data were acquired with a MicroCAT ® II scanner (ImTek Inc., Knoxville, USA). The x-ray tube (40 W, tungsten anode, 35-80kVp source and <50-micron focal spot) was biased at 70 kVp and had 2 mm of added aluminium filtration. The exposure time was 500 ms per projection and tube current was 500 μA. The angular sampling was 1º per projection for a full 360º scan. The x-ray detector of this system is rectangular (2k × 3k) and can image the whole body of a mouse (2048 × 3096 pixel device) in a single rotation. Images were reconstructed using the Feldkamp cone-beam algorithm for filtered backprojection with a ramp filter cutoff at the Nyquist frequency. The CT data were not corrected for scatter or beam hardening artifacts.
The PET data were acquired with a MOSAIC ® scanner (Philips AG, Eindhoven, The Netherlands). This device uses a discrete 2 × 2 × 10 mm 3 gadolinium-oxyorthosilicate (GSO), Anger-logic detector for use in high-resolution (2 mm), highdensity, and high-counting-rate animal PET imaging. It has a 21 cm diameter and 12.8 cm transverse field of view and operates exclusively in 3-dimensional (3D) volume imaging mode. After 12 minutes of data acquisition, images were reconstructed using a RAMLA-3D iterative reconstruction algorithm, giving a pixel size of 1 mm.
The image fusion of the PET and CT data sets was performed by manual image fusion software (AMIDE; freeware; www. crump.ucla.edu/software/amide.adp).
Image Evaluation
The non-attenuation corrected PET images were used for assessing the hypoxia tracer accumulation in each tumor by drawing a region of interest (ROI) as large as possible within the tumor using the anatomical information from CT. For quantification, the slice with the highest mean radiotracer uptake in the tumor was used. Quantification of background uptake was performed by drawing a ROI of the same size within the lower mediastinum.
The CT images of the clinical PET/CT were used for determination of tumor volume. The longest dimension of the tumor in X, Y, and Z as defined by the orientation of the animal in the scanner were measured and the tumor volume was calculated with the volume formula for an ellipse.
Statistical Analysis
For statistical analysis, the paired t-test was used. The tumorto-background ratio of the tumor lesions observed in PET from the clinical PET/CT and the small animal PET were compared and tested for significance using SPSS (Version 11.5). The pvalue is two-sided and subject to a significance level of 0.05.
Results
The examination of tumor-bearing small animals using clinical PET/CT with high-resolution scanning and reconstruction protocols and dedicated small animal PET and dedicated small animal CT revealed good image quality (Fig. 1) . PET identified regions with high tracer uptake, while the CT component provided anatomical details of the mice and allows the discrimination of the source of activity distribution. The dedicated small animal PET scanner shows images with substantial amount of details, whereas the clinical PET system depicts smoothed activity distribution images. A radioactivity accumulation can be seen not only in the hypoxic regions of the tumors but also in the small and large intestine due to the physiological tracer elimination. The acquisition of PET emission data requires a relatively long period of time (12 min) and represents an average position of animal movement, including free-breathing and cardiac motion. The acquisition of CT data is short, up to few seconds for the CT of the clinical PET/CT and up to five minutes for the dedicated small animal CT. Therefore, the average position of organs acquired with PET emission compared to those acquired with CT could vary, especially in the region of the diaphragm. The tumors in our study were localized on the right hind limb, resulting in a less movement of the tumor and a better discrimination of the radiotracer uptake in the tumor.
The measurements of the tumor lesions revealed a 1.89 ± 0.6 higher mean tumor-to-background ratio ± SD for the dedicated small animal PET scanner in comparison to the PET scanner of the clinical PET/CT (P<0.001) ( Fig. 2a) . The mean tumor-to-background ratio of the PET of the clinical PET/CT showed a high correlation with the mean tumor-to-background ratio of the dedicated small animal PET (r 2 = 0.92) (Fig. 2b) . The tumor-to-background ratio of 18 F-FAZA in the subcutaneous EMT6 tumors of the female NMRI nude mice, representing the tumor tissue hypoxia, was independent from the tumor volume ( Fig. 2a ).
Discussion
Over the past few years small animal PET scanners with enhanced spatial resolution and sensitivity have been developed to overcome the limitations of clinical PET scanners in scanning small species (6) . However, small animal PET scanners are only available in a limited number of institutions and, unfortunately, posses the same limitation which is found in any PET im- aging. This is the difficulty in the anatomical localization of lesions. Therefore, several groups have proposed to develop small animal PET/CT scanners, because they provide molecular/metabolic and anatomic/morphologic information, both non-invasively and quantitatively (7, 8) . In combined systems, the CT could be used for precise anatomical localization of increased radiotracer uptake and attenuation correction, eliminating the need for an additional scan and reducing the PET examination time, and measurement of tumor lesions in terms of size and volume (9). However, it will take a few more years before small animal PET/CT scanners are established and widely used for research purposes (10). Clinical PET/CT scanners are widely available, but have lower resolution and sensitivity than small animal PET and small animal CT scanners. However, it is suggested that the lower PET resolution may also be sufficient for small animal imaging, in combination with additional anatomical information from high-resolution CT images (10).
Tatsumi et al. (10) used a clinical PET/CT with integrated 2D PET scanner and a 4-slice CT for their animal studies. The field of view (FOV) chosen for image CT reconstruction was 150 mm and the PET reconstruction resolution was set at 5 to 6 mm. Using this scanning technology, they were able to clearly visualize a 18 F-FDG uptake in tumors of rabbits and rats. In their study, the intratumoral heterogeneity of FDG uptake could not be adequately determined in mice tumors, most likely because the tumors were small in size. However, they suggested that small animal imaging with the recent generation of high performance clinical PET/CT scanners may be adequate for non-invasive imaging in oncological research in mice due to the higher count sensitivity of the 3D PET than the 2D PET and the higher spatial resolution of the 16-slice CT than the 4-slice CT. Our comparative study was performed with a state-of-the-art clinical PET/CT scanner, consisting of a full-ring Pico-3D PET scanner (maximum spatial resolution of 6.3 × 6.3 × 6.0 mm 3 ) and a 16-slice CT (maximum spatial resolution of 0.6 × 0.6 × 0.6 mm 3 ) and compared with a small animal PET (maximum spatial resolution of 2.5 × 2.5 × 3.5 mm 3 ) and a small animal CT (maximum spatial resolution of 0.027 × 0.027 × 0.027 mm 3 ) (11, 12) . The tumor lesions revealed a significantly higher mean tumor-to-background ratio ± SD for the small animal PET scanner than the PET scanner of the clinical PET/CT. The determinant factor for tumor imaging in mice with a clinical PET/CT is the poor spatial resolution and sensitivity of the PET scanner. The crystal size of the PET of the clinical PET/ CT is too large and leads to substantially reduced spatial resolution, which in turn decreases the count recovery in small sized organs and increases the spill-over contributions from surrounding activity. Due to partial volume effects, the images are too blurred to allow an accurate measurement of the activity concentration. Hoffman et al. (13) reported that the size of an object has to be two times the resolution element to obtain correct activity concentration. However, the mean tumor-to-background ratio of the PET of the clinical PET/CT and the small animal PET showed a high correlation. This linear relationship between the two different imaging devices results in spite of partial volume effects due to the limited spatial resolution and spill over effects due to the poor resolution of the clinical PET systems and could be used to apply a correction factor to the PET of the clinical PET/CT.
In agreement with the literature (14), tumor hypoxia does not correlate with tumor volume. Ischemia and hypoxia are not synonymous; the former is a lack of perfusion and can lead to hypoxia, although it may not be evident until the late stages of ischemia. Many solid tumors develop areas of hypoxia during their evolution. This is primarily caused by unregulated cellular growth, resulting in a greater demand on oxygen for energy metabolism. High interstitial pressure may exacerbate the already inefficient vascularization within the tumor. In addition, other factors, such as low O 2 solubility (anemia), might increase levels of tissue hypoxia. Aggressive tumors often have high microvessel density but even higher levels of hypoxia (14).
There are some limitations in this study. Using the MOSA-IC ® system, it is not possible to perform a partial volume, attenuation, or scatter correction. However, we do not believe that the results have been negatively influenced in a way that hampers the current study. CT was performed without the use of an intravenous contrast medium, limiting the collection of additional diagnostic information concerning the differentiation of solid and necrotic tumor portions and tumor vascularity. Furthermore, the results could vary from mice stem cell, tumor cell, and radiotracer. Therefore, further detailed and systematic studies are necessary to clearly define the value and the comparability of our results with other small animal imaging devices, to confirm that the observed correlation not dependents on the tumor model and the tumor localization and to define the minimum tumor size necessary for an accurate assessment with clinical PET/CT.
Conclusions
Small animal imaging has gained increasing attention in recent years as an excellent in vivo evaluation method for oncology, cardiology, and neuroscience research (15). PET/CT scanners facilitate an accurate correlation and evaluation of molecular/metabolic information from PET imaging with anatomical/morphological information from CT imaging (9). Clinical PET/CT yields a clear improvement of diagnostic accuracy over PET and CT alone and is considered to be particularly well suited for clinical routine examinations, but also for in vivo research purposes. Currently, the PET scanner of clinical PET/CT scanner offers an insufficient spatial resolution and sensitivity to obtain meaningful molecular/metabolic information of tracer uptake in small mice tumors. They provide a high correlation with the higher resolution of small animal PET scanners, but it is not proven that this correlation can be used to predict the true activity concentration within the mice tumors. For tumor research in humans and animals using clinical PET/CT scanners, PET scanners with a higher spatial resolution and a higher sensitivity will be highly promising, but will be in competition to PET/MRI (16) .
